GS
PCVX icon

GTS Securities’s Vaxcyte PCVX Stock Holding History

GTS Securities’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-9,700
Closed -$1.11M – 3260
2024
Q3 		$1.11M Buy
+9,700
New +$874K ﹤0.01% 2068

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GTS Securities's PCVX Position: Q4 2024 in Review

GTS Securities sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 1,794 shares — an estimated $205K sold.

GTS Securities first reported a position in PCVX in Q3 2024 and held it in 1 quarter. The position peaked at $205K in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • GTS Securities reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 1,794 Vaxcyte shares in Q4 2024, an estimated $205K.
  • GTS Securities first reported a position in Vaxcyte in Q3 2024 and held it in 1 quarter.
  • GTS Securities's Vaxcyte position peaked at $205K in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.